|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-11-25
|
|
pubmed:abstractText |
SR4554 is a fluorine-containing 2-nitroimidazole, designed as a hypoxia marker detectable with 19F magnetic resonance spectroscopy (MRS). In an initial phase I study of SR4554, nausea/vomiting was found to be dose-limiting, and 1400 mg m(-2) was established as MTD. Preliminary MRS studies demonstrated some evidence of 19F retention in tumour. In this study we investigated higher doses of SR4554 and intratumoral localisation of the 19F MRS signal.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:CampbellM JMJ,
pubmed-author:CrossKK,
pubmed-author:EatonDD,
pubmed-author:HalbergTT,
pubmed-author:JudsonII,
pubmed-author:LeachM OMO,
pubmed-author:LeeC PCP,
pubmed-author:McNamaraJJ,
pubmed-author:OregioniAA,
pubmed-author:PayneG SGS,
pubmed-author:RaynaudF IFI,
pubmed-author:RuddleRR,
pubmed-author:SeddonBB,
pubmed-author:TanSS,
pubmed-author:TracyMM,
pubmed-author:WorkmanPP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1860-8
|
|
pubmed:dateRevised |
2011-3-3
|
|
pubmed:meshHeading |
pubmed-meshheading:19935799-Adult,
pubmed-meshheading:19935799-Aged,
pubmed-meshheading:19935799-Aged, 80 and over,
pubmed-meshheading:19935799-Cell Hypoxia,
pubmed-meshheading:19935799-Female,
pubmed-meshheading:19935799-Humans,
pubmed-meshheading:19935799-Magnetic Resonance Spectroscopy,
pubmed-meshheading:19935799-Male,
pubmed-meshheading:19935799-Middle Aged,
pubmed-meshheading:19935799-Neoplasms,
pubmed-meshheading:19935799-Nitroimidazoles,
pubmed-meshheading:19935799-Oxygen,
pubmed-meshheading:19935799-Partial Pressure,
pubmed-meshheading:19935799-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.
|
|
pubmed:affiliation |
Cancer Research UK Centre for Cancer Therapeutics, Cancer Research UK Clinical Magnetic Resonance Research Group and Section of Medicine, The Institute of Cancer Research and Drug Development Unit, The Royal Marsden Hospital, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
